Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 839

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 839
---
-by-Region, Licensed Product-by-Licensed Product or
Program-by-Program basis, for any or no reason, on [***] prior written notice to WuXi Biologics.

ARTICLE XII

EFFECT OF TERMINATION

12.1 Accrued Obligations. The expiration or termination of this Agreement for any reason shall not
release either Party from any liability which, at the time of such expiration or termination, has already accrued to the other Party or which is attributable to a period prior to such expiration or termination, nor will any termination of this
Agreement preclude either Party from pursuing all rights and remedies it may have under this Agreement, or at law or in equity, with respect to breach of this Agreement. Notwithstanding anything in this Agreement to the contrary, in the event Aadi
does not pay the Closing Payment within the Closing Period, such Closing Payment will not be deemed accrued under this Section 12.1 or otherwise and Aadi shall have no obligation to pay WuXi Biologics the Closing Payment, nor any liability to
WuXi Biologics with respect to the Closing Payment, following expiration of the Agreement under Section 11.1(a).

12.2 Effect of Termination Caused byAadi. This Section 12.2 shall apply solely in the event of any
termination of this Agreement by WuXi Biologics pursuant to Section 11.2 or Section 11.3 or by Aadi pursuant to Section 11.4 or by either Party pursuant to Section 16.12.

(a) Development. In the event Aadi is conducting any ongoing Clinical Trial of Licensed Products following the date a notice of
termination has been issued by WuXi Biologics or Aadi, as applicable, the Parties will negotiate in good faith and adopt a plan to wind-down such activities in an orderly fashion as expeditiously as practicable.

(b) Commercialization. If this Agreement is terminated after the First Commercial Sale of a Licensed Product in the Territory,
Aadi shall have the right, for a period of [***] following such termination (the “Sell-OffPeriod”), to sell (in the Field in the Territory) stocks of Licensed Products on hand at the time of
such termination (and for which Regulatory Approval in the Field in the Territory has been approved prior to such termination). Any Licensed Product sold or disposed by Aadi, its Affiliates or its Sublicensees in the Territory during the Sell-Off Period shall be subject to applicable